Wendel SE (FRA:WIS) (FY 2024) Earnings Call Highlights: Strong Growth in NAV and Dividend ...
Dividend Proposal: EUR 4.7 per share, up 17.5% from the previous year.
Principal Investment Value Creation: EUR 21.1 per share, driven by Bureau Veritas' performance.
Asset Management Contribution: EUR 6 per share, with a 24% growth in Assets under Management (AuM).
Revenue: EUR 8.64 billion, a 13% increase from the previous year, with 8.4% organic growth.
Net Income Group Share: EUR 294 million, double the amount from 2023.
Cash Flow Conversion: Bureau Veritas reported cash conversion above 90%.
EBITDA Margin: CPI maintained a high EBITDA margin at 49.3%.
Stahl EBITDA Margin: 22.2%, with a proforma margin of 23.7% after strategic refocus.
Debt and Liquidity: LTV ratio at 7.2%, with liquidity of EUR 1.2 billion.
Share Buyback: EUR 92.5 million worth of shares repurchased, creating EUR 1.4 per share in value.
Warning! GuruFocus has detected 5 Warning Signs with FRA:WIS.
High Yield Dividend Stocks in Gurus' Portfolio
This Powerful Chart Made Peter Lynch 29% A Year For 13 Years
How to calculate the intrinsic value of a stock?
Release Date: February 27, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Wendel SE (FRA:WIS) reported a 16.9% year-over-year increase in fully diluted net asset value per share, reaching EUR 185.7.
The company proposed a EUR 4.7 per share dividend, up 17.5% from the previous year, reflecting strong financial performance.
Bureau Veritas, a key asset, delivered a 28% increase in share price, contributing significantly to value creation.
The asset management segment showed strong growth, with assets under management increasing by 24% and contributing EUR 6 per share to value.
Wendel SE's strategic transformation over the past two years has resulted in managing EUR 41 billion in assets, diversifying its portfolio and increasing cash flow generation.
Some unlisted assets, such as Stahl, Scalian, and ACAMS, faced challenges due to difficult market conditions and volatile multiples, negatively impacting overall value creation.
The company's LTV ratio increased to 23% after the acquisition of Monroe, surpassing the S&P ceiling for its current rating.
Scalian experienced a 1.2% decline in sales and a drop in EBITDA margin due to market slowdowns in the automotive and aeronautics sectors.
Despite strong performance in some areas, the overall contribution from unlisted assets was negative in 2024.
The company faces a substantial discount to its net asset value, which management attributes to the need for sustained performance improvement.
Q: XR announced a buyback given the large discount to reach NEV. Why not make such a smart capital allocation move? A: Laurent Mignon, Chairman of the Executive Board, Group CEO, explained that while Wendel has conducted buybacks, which created value, the company focuses on long-term value creation through strategic investments in asset management. Share buybacks are part of their strategy but not the sole focus.
Q: The financial press disclosed that Puerto Rico could sell more champagne. Would you have a look at it and make a bid? A: Laurent Mignon stated that Wendel is not interested in investing in the retail and consumer business as they lack expertise in that area.
Q: Can you make any additional comments on the discussions between SGS and Bureau Veritas? A: Laurent Mignon confirmed that discussions between SGS and Bureau Veritas have ceased without an agreement. Wendel supports Bureau Veritas's strategic plan and its transformative growth ambitions.
Q: Are you concerned about potential changes in the carry interest tax scheme in the US for private equity industries? A: Laurent Mignon mentioned that Wendel is not exposed to this issue, so it is not a concern for them. Their exposure to the US is through companies like CPI and ACAMS, and Monroe Capital in private credit, where the impact of carry interest is smaller.
Q: There is still a substantial discount to NAV. How do you explain that and what are you going to do about it? A: Laurent Mignon emphasized that performance is the remedy to the discount. Wendel aims to improve asset performance and provide significant returns to shareholders through dividends and strategic investments. They focus on long-term value creation rather than short-term fixes.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
2 hours ago
- Business Insider
All Eyes on Jackson Hole as Market Momentum Cools - Bybit and FXStreet TradFi Report
Dubai, UAE, August 21st, 2025, Chainwire Bybit, the world's second-largest cryptocurrency exchange by trading volume, issued its latest TradFi report, spotlighting heightened anticipation ahead of the Jackson Hole Economic Policy Symposium. With Federal Reserve Chair Jerome Powell set to speak on Friday, markets are bracing for clarity on the U.S. interest rate outlook and its implications across global assets, from currencies to cryptocurrencies. The report reveals that traders are pricing in an 83% chance of a 25-basis-point rate cut at the Fed's September 17 meeting, down from 94% last week, underscoring rising uncertainty. Historically, Powell's remarks at Jackson Hole have triggered sharp market moves: hawkish tones have lifted the dollar and weighed on equities, while dovish guidance has sparked rallies in stocks and crypto. This year's backdrop: softer inflation, a cooling labor market, and persistent geopolitical frictions, makes the Fed's forward guidance more pivotal than ever. Key Highlights: Event focus: The Jackson Hole Economic Policy Symposium runs Aug. 21–23, with Powell's speech set for Friday at 14:00 GMT. Rate cut expectations: Markets now see an 83% probability of a 25 bps cut in September, down from 94% last week. Dollar impact: Lower rates typically weaken the dollar while boosting risk assets, including crypto. Powell's tone matters: A dovish stance could fuel a EUR/USD breakout; a hawkish tone risks triggering profit-taking. EUR/USD setup: Trading near 1.168, the pair faces resistance at 1.182 and support at 1.16. Neutral technicals: Flat MACD and RSI at 50 reflect market indecision before Powell's remarks. Technical analysis points to EUR/USD trading near 1.168, with resistance at 1.182 and support around 1.16. Indicators show neutrality, suggesting traders are holding back until Powell delivers direction. A dovish tone could push EUR/USD toward the 1.20 level, while a hawkish surprise may strengthen the dollar and trigger profit-taking. For crypto and broader risk assets, the stakes remain high. Lower rates tend to weaken the dollar and drive capital toward alternative investments, with Bitcoin, Ethereum, and Solana already reacting to shifting macro expectations. For detailed insights, readers may read the full report. #Bybit / #TheCryptoArk /#BybitResearch About Bybit Bybit is the world's second-largest cryptocurrency exchange by trading volume, serving a global community of over 70 million users. Founded in 2018, Bybit is redefining openness in the decentralized world by creating a simpler, open, and equal ecosystem for everyone. With a strong focus on Web3, Bybit partners strategically with leading blockchain protocols to provide robust infrastructure and drive on-chain innovation. Renowned for its secure custody, diverse marketplaces, intuitive user experience, and advanced blockchain tools, Bybit bridges the gap between TradFi and DeFi, empowering builders, creators, and enthusiasts to unlock the full potential of Web3. Discover the future of decentralized finance at Contact Head of PR Bybit
Yahoo
8 hours ago
- Yahoo
Quantum BioPharma Announces Corporate Updates
TORONTO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) ('Quantum BioPharma' or the 'Company'), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, today announces the following corporate updates: Debt Settlement On August 12, 2025, the board of directors of the Company (the 'Board') authorized the settlement of outstanding debt with one (1) creditor in the amount of $26,812.50 USD by converting the debt into 1,102 Class B Shares ('Creditor Shares') at a deemed price of $24.33 USD per Class B Share. Grant of Restricted Stock Units On August 15, 2025, the Board authorized and approved the grant of restricted share units (each, an 'RSU') pursuant to the Equity Incentive Plan. The Company granted 800 RSUs each to Peter Stys and Jack Antel (each a 'Clinical Advisor'). The RSUs granted vest in accordance with the following schedule: 500 RSUs will vest to each Clinical Advisor when the Company has a filing application with the US FDA or an equivalent regulatory filing in another country for the start of a clinical Phase 2 trial for Lucid MS within 1 year of grant. 300 RSUs will vest to each Clinical Advisor when the Company receives a no objection letter or an equivalent regulatory approval from the US FDA or other regulatory institution permitting the start of the clinical trial. Statutory Hold Period and Restrictions on Resale The Creditor Shares and RSUs (and any Class B Shares issuable upon their settlement) are subject to a statutory hold period of four months and one day pursuant to the policies of the CSE. The RSU's and Creditor Shares were not registered under the U.S. Securities Act and are not permitted to be offered or sold within the United States absent such registration or an applicable exemption from the registration requirements therein. Change to Advisory Board Effective August 15, 2025, the Company terminated the Board Advisor Agreement dated July 1, 2025, with Kevin Malone, and as a result, Mr. Malone is no longer serving as an Advisor to the Company's Board of Directors. About Quantum BioPharma Ltd. Quantum BioPharma (NASDAQ: QNTM) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. ('Lucid'), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented unbuzzd™ and spun out its OTC version to a company, Celly Nutrition Corp. ('Celly Nutrition'), now Unbuzzd Wellness Inc., led by industry veterans. Quantum BioPharma retains ownership of 20.10% (as of June 30, 2025) of Unbuzzd Wellness Inc. at The agreement with Unbuzzd Wellness Inc. also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. Quantum BioPharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property. For more information visit Forward-Looking Information This press release contains forward-looking statements under applicable securities laws, identified by terms like "may," "should," "anticipate," "expect," "potential," "believe," or "intend." These statements, based on assumptions and expected future events, involve risks and uncertainties that may cause actual results to differ materially from those expressed. For more details on risks, see Quantum BioPharma's filings on SEDAR+ ( and EDGAR ( Readers should not rely unduly on these statements, as there is no assurance that plans or expectations will occur. The Company assumes no obligation to update these statements except as required by law. The reader is urged to refer to additional information relating to Quantum BioPharma, including its annual information form, which can be located on the SEDAR+ website at and on the EDGAR section of the United States Securities and Exchange Commission's website at for a more complete discussion of such risk factors and their potential effects. Contacts: Quantum BioPharma Ltd. Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board Email: Zsaeed@ (833) 571-1811 Investor Relations Investor Relations: IR@ Inquiries: info@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11 hours ago
- Yahoo
Does Perdoceo Education (NASDAQ:PRDO) Deserve A Spot On Your Watchlist?
Explore Perdoceo Education's Fair Values from the Community and select yours For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it currently lacks a track record of revenue and profit. But as Peter Lynch said in One Up On Wall Street, 'Long shots almost never pay off.' While a well funded company may sustain losses for years, it will need to generate a profit eventually, or else investors will move on and the company will wither away. If this kind of company isn't your style, you like companies that generate revenue, and even earn profits, then you may well be interested in Perdoceo Education (NASDAQ:PRDO). Now this is not to say that the company presents the best investment opportunity around, but profitability is a key component to success in business. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. Perdoceo Education's Earnings Per Share Are Growing Generally, companies experiencing growth in earnings per share (EPS) should see similar trends in share price. That makes EPS growth an attractive quality for any company. Perdoceo Education managed to grow EPS by 14% per year, over three years. That's a good rate of growth, if it can be sustained. One way to double-check a company's growth is to look at how its revenue, and earnings before interest and tax (EBIT) margins are changing. Perdoceo Education maintained stable EBIT margins over the last year, all while growing revenue 16% to US$769m. That's progress. The chart below shows how the company's bottom and top lines have progressed over time. To see the actual numbers, click on the chart. View our latest analysis for Perdoceo Education While it's always good to see growing profits, you should always remember that a weak balance sheet could come back to bite. So check Perdoceo Education's balance sheet strength, before getting too excited. Are Perdoceo Education Insiders Aligned With All Shareholders? It should give investors a sense of security owning shares in a company if insiders also own shares, creating a close alignment their interests. Shareholders will be pleased by the fact that insiders own Perdoceo Education shares worth a considerable sum. Notably, they have an enviable stake in the company, worth US$138m. Holders should find this level of insider commitment quite encouraging, since it would ensure that the leaders of the company would also experience their success, or failure, with the stock. Does Perdoceo Education Deserve A Spot On Your Watchlist? As previously touched on, Perdoceo Education is a growing business, which is encouraging. For those who are looking for a little more than this, the high level of insider ownership enhances our enthusiasm for this growth. That combination is very appealing. So yes, we do think the stock is worth keeping an eye on. We don't want to rain on the parade too much, but we did also find 1 warning sign for Perdoceo Education that you need to be mindful of. While opting for stocks without growing earnings and absent insider buying can yield results, for investors valuing these key metrics, here is a carefully selected list of companies in the US with promising growth potential and insider confidence. Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
